Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betulaceae allergenic extract is a biological allergen extract developed by LOFARMA S.p.A. for use in allergen-specific immunotherapy (ASIT). Derived from the pollen of plants in the Betulaceae family, particularly *Betula verrucosa* (birch), the extract is intended for the treatment of respiratory allergies, including allergic rhinitis and allergic asthma, in sensitized patients. It functions as a therapeutic vaccine that modulates the IgE-mediated immune response to birch pollen allergens, with the major target being the Bet v 1 allergen. The extract has been evaluated in Phase 2 clinical trials for biological standardization to determine its potency in histamine equivalent prick (HEP) units and to establish reference preparations for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betulaceae allergenic extract.